Aminu Levin
Malignant melanoma, usually referred to as melanoma, is a kind of skin cancer that arises from melanocytes, or cells that produce colour. In those with low amounts of the skin pigment melanin, exposure to UV radiation is the main cause of melanoma. Surgery is often used as a kind of treatment. It may be possible to check for spread in the adjacent lymph nodes in those with somewhat bigger tumours. If there hasn't been any spread, most patients are healed. Immunotherapy, biologic treatment, radiation therapy, or chemotherapy could increase survival rates in people whose melanoma has spread. Benefits evaluations for several nations are included in the global HTA database Prismaccess®. In this evaluation, Germany was the main subject. In the previous ten years, all choices about melanoma treatments launched in Germany were taken into account for a systematic reimbursement [1]. A total of 34 IQWiG assessments have been taken into account by the GBA when making judgments. 16 phase III studies, 4 phase II studies, and 2 phase I studies were included in the submissions [2]. A significant added advantage was provided to 11 of the analysed subgroups, two subgroups demonstrated an unquantifiable added benefit, 21 subgroups did not demonstrate an added benefit, and the G-BA chose a smaller benefit in two subgroups. In all, the 22 choices resulted in 12 recommendations without restrictions, 9 recommendations with restrictions, and in and Nivolumab in combination with ipilimumab in non-pretreated patients with a BRAF V600 wild-type tumour did not produce a beneficial additional benefit. In any case, Germany has access to all medications [3].
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi